Salud financiera de hoja de balance de Puma Biotechnology
Salud financiera controles de criterios 5/6
Puma Biotechnology tiene un patrimonio de accionistas total de $48.5M y una deuda total de $89.1M, lo que sitúa su ratio deuda-patrimonio en 183.6%. Sus activos y pasivos totales son $205.0M y $156.5M respectivamente. El BAIT de Puma Biotechnology es de $19.5M, por lo que su ratio de cobertura de intereses es de 2. Tiene efectivo e inversiones a corto plazo que ascienden a $96.8M.
Información clave
183.6%
Ratio deuda-patrimonio
US$89.06m
Deuda
| Ratio de cobertura de intereses | 2x |
| Efectivo | US$96.83m |
| Patrimonio | US$48.51m |
| Total pasivo | US$156.49m |
| Activos totales | US$205.00m |
Actualizaciones recientes sobre salud financiera
Is Puma Biotechnology (NASDAQ:PBYI) A Risky Investment?
Sep 07
Here's Why Puma Biotechnology (NASDAQ:PBYI) Has A Meaningful Debt Burden
Dec 27Puma Biotechnology (NASDAQ:PBYI) Has A Somewhat Strained Balance Sheet
Sep 08We Think Puma Biotechnology (NASDAQ:PBYI) Can Stay On Top Of Its Debt
Dec 14Puma Biotechnology (NASDAQ:PBYI) Takes On Some Risk With Its Use Of Debt
Sep 05Recent updates
Is Puma Biotechnology (NASDAQ:PBYI) A Risky Investment?
Sep 07Lacklustre Performance Is Driving Puma Biotechnology, Inc.'s (NASDAQ:PBYI) 26% Price Drop
Aug 15The Market Doesn't Like What It Sees From Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Earnings Yet As Shares Tumble 25%
Jun 07Here's Why We Think Puma Biotechnology (NASDAQ:PBYI) Might Deserve Your Attention Today
Jun 05We Like The Quality Of Puma Biotechnology's (NASDAQ:PBYI) Earnings
May 09Puma Biotechnology: A Story In Flux Heading Into Mid-2024
May 05Is There An Opportunity With Puma Biotechnology, Inc.'s (NASDAQ:PBYI) 46% Undervaluation?
Apr 10There's Reason For Concern Over Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Massive 31% Price Jump
Mar 01Here's Why Puma Biotechnology (NASDAQ:PBYI) Has A Meaningful Debt Burden
Dec 27Puma Biotechnology (NASDAQ:PBYI) Has A Somewhat Strained Balance Sheet
Sep 08Puma Biotechnology, Inc. (NASDAQ:PBYI) Held Back By Insufficient Growth Even After Shares Climb 34%
Apr 17We Think Puma Biotechnology (NASDAQ:PBYI) Can Stay On Top Of Its Debt
Dec 14Puma Biotechnology, Takeda enter licensing agreement for cancer treatment alisertib
Sep 20Puma Biotechnology (NASDAQ:PBYI) Takes On Some Risk With Its Use Of Debt
Sep 05Puma Biotechnology Non-GAAP EPS of $0.28, revenue of $59.5M
Aug 04Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo ($137.7M) de PBYI superan a sus pasivos a corto plazo ($104.3M).
Pasivo a largo plazo: Los activos a corto plazo de PBYI ($137.7M) superan a sus pasivos a largo plazo ($52.2M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: PBYI tiene más efectivo que su deuda total.
Reducción de la deuda: El ratio deuda-patrimonio de PBYI ha pasado de 429.2% a 183.6% en los últimos 5 años.
Cobertura de la deuda: La deuda de PBYI está bien cubierta por el flujo de caja operativo (37.4%).
Cobertura de intereses: Los pagos de intereses de la deuda de PBYI no están bien cubiertos por el BAIT (2x cobertura).